Secular Trends in Opportunistic Infections, Cancers and Mortality in Patients with AIDS During the Era of Modern Combination Antiretroviral Therapy

Overview

Journal HIV Med

Publisher Wiley

Specialty Infectious Diseases

Date 2018 Mar 25

PMID 29573311

Citations 7

Authors

E Sezgin

M L Van Natta

J E Thorne

M A Puhan

D A Jabs

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study was to estimate the incidence of, determine risk factors for, and investigate the consequences of opportunistic infections (OIs) and malignancies among patients with the acquired immune deficiency syndrome (AIDS) in the era of modern combination antiretroviral therapy (cART).

Methods: Three enrolment periods (1998-2002, 2003-2005 and 2006-2012), corresponding to changes in predominant cART regimens, were compared among 1889 participants enrolled in a prospective cohort study, the Longitudinal Study of Ocular Complications of AIDS (LSOCA). Incidences of AIDS-related OIs and cancers were estimated. Multivariate logistic and Cox regression models were used to determine the effect of demographic and clinical characteristics on OIs and mortality.

Results: Between participants enrolled in the 1998-2002 and 2006-2012 enrolment periods, the incidence of OIs decreased from 27 per 1000 person-years (PY) to 11 per 1000 PY (P < 0.001), and mortality decreased from 41 per 1000 PY to 18 per 1000 PY (P < 0.0001), corresponding to improvements in cART regimens.

Conclusions: Improvements in cART regimens led to a progressive decline in the incidence of OIs and mortality between 1999 and 2013 among patients with AIDS in the era of modern cART.

Citing Articles

Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus.

Tang J, Zhang K, Fang T, Weng R, Liang Z, Yan X World J Gastroenterol. 2023; 29(11):1745-1756.

PMID: 37077518 PMC: 10107211. DOI: 10.3748/wjg.v29.i11.1745.

Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study.

Deibel A, Meyer Zu Schwabedissen C, Husmann L, Grimm F, Deplazes P, Reiner C Pathogens. 2022; 11(4).

PMID: 35456117 PMC: 9032794. DOI: 10.3390/pathogens11040441.

Different Trends of Distinct Time Points of AIDS Events Following HIV Diagnosis in Various At-risk Populations: A Retrospective Nationwide Cohort Study in Taiwan.

Lee C, Wu P, Lu P, Liang F Infect Dis Ther. 2021; 10(3):1715-1732.

PMID: 34245451 PMC: 8322356. DOI: 10.1007/s40121-021-00494-8.

Treatment and Prevention of Histoplasmosis in Adults Living with HIV.

McKinsey D J Fungi (Basel). 2021; 7(6).

PMID: 34071599 PMC: 8229061. DOI: 10.3390/jof7060429.

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.

Guo P, He H, Chen X, Chen J, Chen X, Lan Y Front Pharmacol. 2021; 11:569766.

PMID: 33841131 PMC: 8027496. DOI: 10.3389/fphar.2020.569766.

References

Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D . Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008; 48(5):590-8. DOI: 10.1097/QAI.0b013e31817efb54. View

Mocroft A, Katlama C, Johnson A, Pradier C, Antunes F, Mulcahy F . AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000; 356(9226):291-6. DOI: 10.1016/s0140-6736(00)02504-6. View

Long J, Engels E, Moore R, Gebo K . Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008; 22(4):489-96. PMC: 2553213. DOI: 10.1097/QAD.0b013e3282f47082. View

Buchacz K, Baker R, Moorman A, Richardson J, Wood K, Holmberg S . Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS. 2008; 22(11):1345-54. DOI: 10.1097/QAD.0b013e328304b38b. View

Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S . Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005; 37(6-7):482-7. DOI: 10.1080/00365540510035328. View

Kaplan J, Benson C, Holmes K, Brooks J, Pau A, Masur H . Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58(RR-4):1-207. View

Murphy E, Collier A, Kalish L, Assmann S, Para M, Flanigan T . Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001; 135(1):17-26. DOI: 10.7326/0003-4819-135-1-200107030-00005. View

Gebo K, Fleishman J, Moore R . Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005; 40(5):609-16. DOI: 10.1097/01.qai.0000171727.55553.78. View

Jones J, Hanson D, Dworkin M, Ward J, Jaffe H . Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1:S11-7. View

10.

Jabs D, Van Natta M, Holbrook J, Kempen J, Meinert C, Davis M . Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology. 2007; 114(4):787-93. DOI: 10.1016/j.ophtha.2006.07.065. View

11.

Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K . Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006; 20(5):741-9. DOI: 10.1097/01.aids.0000216375.99560.a2. View

12.

Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N . The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer. 2004; 100(12):2644-54. DOI: 10.1002/cncr.20309. View

13.

Jones J, Hanson D, Dworkin M, Alderton D, Fleming P, Kaplan J . Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 2002; 48(2):1-22. View

14.

Crum-Cianflone N, Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel R . Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors' reply. AIDS. 2009; 23(13):1791-2. DOI: 10.1097/QAD.0b013e32832cb296. View

15.

Puhan M, Van Natta M, Palella F, Addessi A, Meinert C . Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis. 2010; 51(8):947-56. PMC: 2943970. DOI: 10.1086/656415. View

16.

Detels R, Tarwater P, Phair J, Margolick J, Riddler S, Munoz A . Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001; 15(3):347-55. DOI: 10.1097/00002030-200102160-00008. View

17.

Moore R, Chaisson R . Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999; 13(14):1933-42. DOI: 10.1097/00002030-199910010-00017. View

18.

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

19.

Maurer T, Ponte M, Leslie K . HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007; 357(13):1352-3. DOI: 10.1056/NEJMc070508. View

20.

Kaplan J, Hanson D, Dworkin M, Frederick T, Bertolli J, Lindegren M . Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000; 30 Suppl 1:S5-14. DOI: 10.1086/313843. View